Anand Sharma, MD, D.Phil, MRCP, MBBS, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood, UK, challenges oncologists to improve 5-year survival in advanced renal cell cancer (aRCC). Despite a large quantity of first-line immunotherapy options, Dr Sharma points out up to 50% of patients are unresponsive and require further treatment. To find first-line options for patients with no treatment specific biomarkers is one of the biggest challenges for aRCC researchers. This interview took place at the American Clinical Society of Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть